Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer

Investigational New Drugs

Volumn 30, Issue 3, 2012, Pages 1132-1137

  Okamoto, Isamu ^a   Yamamoto, Nobuyuki ^b   Kubota, Kaoru ^c   Ohe, Yuichiro ^d   Nogami, Naoyuki ^e   Murakami, Haruyasu ^b   Yamaya, Hidetoshi ^f   Ono, Katsuhiro ^f   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^f TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Carboplatin; Nab paclitaxel; Non small cell lung cancer; Pharmacokinetics; Safety

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DETERMINATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; JAPANESE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA;

ADULT; AGED; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL;

EID: 84864351930     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9674-9     Document Type: Article

References (16)

1. Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300
2. Azzoli CG, Baker S Jr, Temin S et al (2009) American Society of Clinical Oncology Clinical Practice Guideline update on chemo-therapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251-6266
3. Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247-1259 (Pubitemid 20239995)
4. Weiss RB, Donehower RC, Wiernik PH et al (1990) Hypersen-sitivity reactions from taxol. J Clin Oncol 8:1263-1268
5. Gelderblom H, Verweij J, Nooter K et al (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590-1598 (Pubitemid 32778603)
6. Kloover JS, den Bakker MA, Gelderblom H et al (2004) Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 90:304-305 (Pubitemid 38250619)
7. Nyman DW, Campbell KJ, Hersh E et al (2005) Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formula-tion of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 23:7785-7793 (Pubitemid 46657375)
8. Sparreboom A, van Zuylen L, Brouwer E et al (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59:1454-1457 (Pubitemid 29160110)
9. Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with poly-ethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794-7803 (Pubitemid 46657376)
10. Green MR, Manikhas GM, Orlov S et al (2006) Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 17:1263-1268 (Pubitemid 44288216)
11. Rizvi NA, Riely GJ, Azzoli CG et al (2008) Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 26:639-643 (Pubitemid 351264360)
12. Socinski MA, Manikhas GM, Stroyakovsky DL et al (2010) A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 5:852-861
13. Ohe Y, Ohashi Y, Kubota K et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitax-el, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18:317-323 (Pubitemid 46323100)
14. Stinchcombe TE, Socinski MA, Walko CM et al (2007) Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients solid tumors. Cancer Chemother Pharmacol 60:759-766 (Pubitemid 47247287)
15. Huizing MT, van Warmerdam LJ, Rosing H et al (1997) Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol 15:1953-1964 (Pubitemid 27209526)
16. Calvert AH, Egorin MJ (2002) Carboplatin dosing formulae: gender bias and the use ofcreatinine-based methodologies. Eur J Cancer 38:11-16 (Pubitemid 34031819)